ADVERTISEMENT
Granules India Q4 Review: Motilal Oswal Maintains 'Buy' Post Inline Results, But Cuts Target Price
Gagillapur remediation, Senn integration weigh on near-term profitability, says Motilal Oswal
29 May 2025, 11:13 AM IST 
Granules India's Q4 FY25 sales grew 1.8% YoY to Rs 11.9 billion, led by increased sales in the finished dosage formulation segment.
(Granules India Ltd.'s manufacturing facility at Gagillapur photo source: Company)
Granules India delivered a slightly better-than-expected revenue in Q4 FY25. However, it reported largely in-line Ebitda/PAT for the quarter. Granules India achieved the highest-ever gross margin on a quarterly basis, fueled by a strategic shift of product mix towards finished dosage formulation.
